NCT06281860 (PITHAC) is a Phase 1 clinical trial of Cisplatine Teva® in Mesothelioma, Malignant, sponsored by Dr Jean Yannis PERENTES.

Who is sponsoring NCT06281860?

NCT06281860 is sponsored by Dr Jean Yannis PERENTES.

What drugs are being tested in NCT06281860?

Interventions in NCT06281860: Cisplatine Teva®.

What condition does NCT06281860 study?

NCT06281860 studies Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma Breast Stage IV, Ovarian Cancer, Esophageal Cancer, Gastric Cancer.

Is NCT06281860 still recruiting?

NCT06281860 is currently status unknown. Last updated 28 February 2024.

Last reviewed 2024-02-28 · How we verify

NCT06281860: PITHAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration

Status unknown Phase 1 Last updated 28 February 2024

What this trial tests

Phase 1 trial testing Cisplatine Teva® in Mesothelioma, Malignant in 39 participants. Status unknown.

Timeline

24 November 2023

Primary endpoint
1 December 2025

1 February 2026

Quick facts

Lead sponsor	Dr Jean Yannis PERENTES
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	24 November 2023
Primary completion	1 December 2025
Estimated completion	1 February 2026
Sites	1 location across Switzerland

Drugs / interventions tested

Cisplatine Teva® — full drug profile →

Conditions studied

Mesothelioma, Malignant — all drugs for Mesothelioma, Malignant →
Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →
Carcinoma Breast Stage IV — all drugs for Carcinoma Breast Stage IV →
Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Dr Jean Yannis PERENTES — full company profile →

Who can join

18 and older, any sex, with Mesothelioma, Malignant or Carcinoma, Non-Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura. This will be followed by an expansion phase at the recommended dose (RD).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer.
Chaudhry Z, Boyadzhyan A, Sasaninia K, Rai V. · · 2024 · cited 3× · PMID 38920970 · DOI 10.3390/antib13020046
Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis.
Chriqui LE, Abdelnour-Berchtold E, Zanfrini E, Devesa-Perez S, et al · · 2024 · cited 1× · PMID 39708537 · DOI 10.1016/j.ctarc.2024.100858
The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions.
Semenova Y, Burkitbayev Z, Kalibekov N, Digay A, et al · · 2025 · PMID 40647443 · DOI 10.3390/cancers17132143

Verify or expand the search:

Other recruiting trials for Mesothelioma, Malignant

Currently open trials in the same condition.

NCT07126509 — Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma · NA · recruiting
NCT06057935 — A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma · Phase 2 · recruiting
NCT06946498 — First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis. · NA · recruiting
NCT05451849 — A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer · Phase 1, PHASE2 · active not recruiting
NCT04104776 — A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06281860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr Jean Yannis PERENTES
Last refreshed: 28 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06281860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing